Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test could speed up lung cancer treatment decisions

NCT ID NCT07649629

Knowledge-focused Sponsor: Regina Elena Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test called liquid biopsy can quickly find genetic changes in people with advanced lung cancer. About 70 adults will give a blood sample, and researchers will compare the results to standard tissue biopsies. The goal is to see if this approach is faster and reliable enough to use in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that a simple blood test can speed up genetic testing for lung cancer, helping doctors choose treatments faster.
What could go wrong
This is a small, early-stage observational study. The liquid biopsy is for research only and won't guide treatment yet. It may not match tissue biopsy results or be fast enough to change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes adult patients with radiological suspicion of locally advanced lung cancer not suitable for locoregional treatment or metastatic lung cancer. Participants are enrolled before completion of the standard diagnostic pathway, when tissue biopsy or cytological sampling is planned but not yet performed, or has already been performed without an available histopathological diagnosis of NSCLC. Eligible patients are recruited at participating centers during thoracic surgery assessment or the first oncology visit and undergo plasma-based liquid biopsy while continuing the standard diagnostic pathway.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Radiological suspicion of locally advanced lung cancer not amenable to locoregional treatment or metastatic lung cancer (stage III-IV). * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. * Tissue biopsy and/or cytological sampling planned but not yet performed, or already performed without an available histopathological diagnosis of non-small cell lung cancer (NSCLC). * Written informed consent for study participation and personal data processing obtained before any study-specific procedure. Exclusion Criteria: * Previous or current history of non-small cell lung cancer (NSCLC). * Histopathological diagnosis of NSCLC already available following tissue biopsy. * Eligibility for surgical removal of tumor tissue. * Ongoing or previous systemic oncological treatment for lung cancer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced non-small cell lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced non-small cell lung cancer (NSCLC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IFO-IRE, Istituto Nazionale Tumori Regina Elena

    RECRUITING

    Roma, RM, 00144, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.